Attention-deficit/hyperactivity disorder drug pipeline
- ICD-11 6A05
- MeSH D001289
6 compounds from 6 companies are in active clinical development for attention-deficit/hyperactivity disorder, including 2 at Phase 3 or beyond.
Mechanisms: Small molecule (4) · Natural product (1) · Psychedelic (1)
Pipeline data compiled October 2026 · every fact sourced.
Upcoming readouts & recent results
FDA approved SIMTRIYO (centanafadine) on the 2026-07-24 PDUFA date for ADHD in adults and pediatric patients aged 6+ ↗
Phase 3b topline: centanafadine XR 280 mg met primary endpoint in adults with ADHD and comorbid anxiety (AISRS LS mean change -18.5 vs -12.6 placebo at week 8) ↗
Phase 2 Part II of PDC-1421 (ABV-1505) in adult ADHD: posted results show no responder advantage over placebo (placebo 50%, low dose 39%, high dose 42%) ↗
FOCUS Phase 3 of solriamfetol in adult ADHD met its primary AISRS endpoint and key secondary endpoints (150 mg). ↗
Compounds in development (6)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| CentanafadinePriority Review | Otsuka Pharmaceutical Co., Ltd. | Approved | Approved | NET Reuptake inhibitor |
| Solriamfetol (Sunosi) | Axsome Therapeutics, Inc. | Phase 3 | Active | NET Reuptake inhibitor |
| PDC-1421 | ABVC BioPharma, Inc. | Phase 2 | Completed | NET Reuptake inhibitor |
| Ampreloxetine | Theravance Biopharma, Inc. | Discontinued | Discontinued | NET Reuptake inhibitor |
| Lysergide D-tartrate (MM120 / LSD) | Definium Therapeutics, Inc. | Discontinued | Discontinued | 5-HT2A Partial agonist |
| SPN-810 (molindone ER)FDA Fast Track (Impulsive Aggression In ADHD; Granted 2014-08-14) | Supernus Pharmaceuticals, Inc. | Discontinued | Discontinued | D2 Antagonist |
Trials recruiting now (42)
42 drug-interventional attention-deficit/hyperactivity disorder trials recruiting now, of 652 registered interventional trials. Browse all on ClinicalTrials.gov →
methylphenidate HCl, Mixed amphetamine salts extended release
methylphenidate hydrochloride (Jornay PM)
CNS Stimulant, Placebo
Adderall XR (mixed salts amphetamine), Placebo
Guanfacine (GUA), Methylphenidate (MPH)
- Phase 4PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder
PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.
Clonidine extended release oral suspension, Placebo
Methylphenidate Hydrochloride Extended Release Capsule
Dyanavel XR, Placebo
- Phase 4Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
100mg SPN-812, Placebo
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Quillivant XR, Placebo
Showing the 12 most advanced of 42 recruiting drug trials · see all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for attention-deficit/hyperactivity disorder?
- 6 compounds from 6 companies are in active clinical development for attention-deficit/hyperactivity disorder, including 2 at Phase 3 or beyond.
- Which attention-deficit/hyperactivity disorder drugs are in Phase 3?
- Phase 3 (or later) programs for attention-deficit/hyperactivity disorder include Centanafadine and Solriamfetol (Sunosi).
- How many clinical trials are recruiting for attention-deficit/hyperactivity disorder?
- 42 drug-interventional attention-deficit/hyperactivity disorder trials are currently recruiting participants, out of 652 registered interventional trials.